My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

51.78 -0.36 (-0.69%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

39 40 Next >

Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates ↗

April 28, 2024

The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for...

Via Talk Markets

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study ↗

April 25, 2024

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.

Via Benzinga

Sanofi (SNY) Q1 2024 Earnings Call Transcript ↗

April 25, 2024

SNY earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday ↗

April 25, 2024

Via Benzinga

How Is The Market Feeling About Sanofi? ↗

March 27, 2024

Via Benzinga

(SNY) - Analyzing Sanofi's Short Interest ↗

March 08, 2024

Via Benzinga

Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings ↗

April 25, 2024

Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to...

Via Benzinga

SNY Stock Earnings: Sanofi Beats EPS, Beats Revenue for Q1 2024 ↗

April 25, 2024

SNY stock results show that Sanofi beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags ↗

April 25, 2024

AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.

Via Investor's Business Daily

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick ↗

April 17, 2024

Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...

Via Benzinga

Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years ↗

April 17, 2024

Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed.

Via Benzinga

US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst ↗

April 25, 2024

The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META)

Via Benzinga

Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity ↗

April 17, 2024

Discover results from Sanofi's Phase 2 study on frexalimab for relapsing multiple sclerosis. Explore sustained reduction in disease activity and lesion numbers with low relapse rates.

Via Benzinga

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗

April 21, 2024

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

Via Benzinga

Novo Nordisk Arms Wegovy to Be a Triple Threat

April 15, 2024

Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders

Via MarketBeat

Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says ↗

April 12, 2024

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough...

Via Benzinga

The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today ↗

April 11, 2024

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

Via InvestorPlace

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says ↗

April 10, 2024

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the...

Via Benzinga

Why Is Auddia (AUUD) Stock Up 192% Today? ↗

April 08, 2024

Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.

Via InvestorPlace

Topics Artificial Intelligence

AIRC Stock Alert: Blackstone Is Taking Apartment Income REIT Private ↗

April 08, 2024

Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.

Via InvestorPlace

Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts ↗

April 08, 2024

Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward.

Via InvestorPlace

Topics Workforce

In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster ↗

April 04, 2024

Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed.

Via Benzinga

Topics Lawsuit

What's Going On European Pharma Giant AstraZeneca Stock On Wednesday? ↗

March 27, 2024

Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca...

Via Benzinga

Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath' ↗

March 26, 2024

Krispy Kreme's partnership with McDonald's has led to a surge in stock prices. Investors are turning to insulin stocks to capitalize on the growing demand.

Via Benzinga

To the Moon and Beyond: 7 Stocks With Cosmic Potential ↗

March 14, 2024

With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.

Via InvestorPlace

Passport to Profits: 7 Global Growth Gems to Diversify Your Holdings ↗

March 13, 2024

With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities.

Via InvestorPlace

Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits ↗

March 04, 2024

Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.

Via InvestorPlace

11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗

February 28, 2024

A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.

Via Benzinga

3 Cash Cow Dividend Stocks for Outsized Income & Upside ↗

February 27, 2024

With uncertainty again weighing on the market, investors can take shelter under these cash cow dividend stocks.

Via InvestorPlace

6 reasons to buy Teva Pharmaceuticals stock sooner than later

February 26, 2024

Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why

Via MarketBeat

Topics Lawsuit

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.